Publication Type : Journal Article
Source : BMJ Case Rep. 2022 Apr 1;15(4):e248782. doi: 10.1136/bcr-2022-248782.PMID: 35365472
Url : https://pubmed.ncbi.nlm.nih.gov/35365472/
Campus : Kochi
School : School of Medicine
Department : Dermatology, Medical Oncology
Verified : Yes
Year : 2022
Abstract :
Cyclin dependent kinase (CDK) 4/6 inhibitors are targeted agents which act on cyclin-D and these combined with hormonal therapy have been approved for the treatment of locally advanced or metastatic breast cancer. CDK 4/6 inhibitors have been found to have a tolerable adverse event profile; however, they have been associated with various dermatological adverse events. We report a case of ribociclib-induced vitiligo and discuss the clinical, dermoscopic and histological features with a review of the various possible pathomechanisms involved.
Cite this Research Publication : Anjaneyan G, Keechilat P, Duraisamy P, Eapen M., "Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation," BMJ Case Rep. 2022 Apr 1;15(4):e248782. doi: 10.1136/bcr-2022-248782.PMID: 35365472